MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
03 mai 2024 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
NFI announces first quarter 2024 results
02 mai 2024 16h30 HE
|
NFI Group Inc
All figures quoted in U.S. dollars unless otherwise noted: 2024 Q1 revenue of $723 million; 1,127 equivalent units ("EUs") delivered, up 42% from 2023 Q1, with 201 of EUs delivered being...
CTO Realty Growth Reports First Quarter 2024 Operating Results
02 mai 2024 16h10 HE
|
CTO Realty Growth, Inc.
WINTER PARK, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced its operating results and earnings for the quarter ended March 31,...
Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
02 mai 2024 16h10 HE
|
Quoin Pharmaceuticals, Inc.
ASHBURN, Va., May 02, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan...
LeMaitre Q1 2024 Financial Results
02 mai 2024 16h05 HE
|
LeMaitre Vascular, Inc.
BURLINGTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q1 2024 results, announced a $0.16/share quarterly...
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
02 mai 2024 16h05 HE
|
Cardiff Oncology, Inc.
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated...
Kura Oncology Reports First Quarter 2024 Financial Results
02 mai 2024 16h05 HE
|
Kura Oncology, Inc.
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive...
EMCORE Corporation to Host Fiscal 2024 Second Quarter Conference Call on May 8, 2024
02 mai 2024 16h03 HE
|
EMCORE Corporation
EMCORE Corporation to Host Fiscal 2024 Second Quarter Conference Call on May 8, 2024
Gevo Reports First Quarter 2024 Financial Results
02 mai 2024 16h01 HE
|
Gevo, Inc.
ENGLEWOOD, Colo., May 02, 2024 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) (“Gevo”, the “Company”, “we”, “us” or “our”) today announced financial results for the first quarter 2024 and recent...
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
02 mai 2024 16h00 HE
|
aTyr Pharma, Inc.
aTyr Pharma announces first quarter 2024 results and provides corporate update